BR100 Increased By (0.63%)
BR30 Increased By (0.86%)
KSE100 Increased By (0.68%)
KSE30 Increased By (0.74%)
AGHA 6.50 Increased By ▲ 0.12 (1.88%)
BECO 4.34 Decreased By ▼ -0.01 (-0.23%)
BML 62.25 Decreased By ▼ -0.30 (-0.48%)
BOP 31.50 Increased By ▲ 0.11 (0.35%)
CNERGY 11.84 Increased By ▲ 0.11 (0.94%)
CSIL 5.97 Increased By ▲ 0.06 (1.02%)
FCCL 61.75 Increased By ▲ 0.04 (0.06%)
FFL 14.87 Increased By ▲ 0.08 (0.54%)
FNEL 1.29 Increased By ▲ 0.05 (4.03%)
KEL 6.35 Increased By ▲ 0.03 (0.47%)
KOSM 5.91 Increased By ▲ 0.01 (0.17%)
LOTCHEM 24.88 Increased By ▲ 0.19 (0.77%)
MLCF 105.00 Increased By ▲ 1.07 (1.03%)
NBP 174.25 Increased By ▲ 0.93 (0.54%)
NCPL 52.10 Increased By ▲ 0.27 (0.52%)
NPL 54.51 Increased By ▲ 0.48 (0.89%)
OGDC 319.50 Increased By ▲ 3.63 (1.15%)
PACE 9.31 Increased By ▲ 0.05 (0.54%)
PAEL 36.00 Increased By ▲ 0.42 (1.18%)
PIBTL 13.78 Increased By ▲ 0.12 (0.88%)
PPL 228.10 Increased By ▲ 2.03 (0.9%)
PRL 81.10 Increased By ▲ 0.82 (1.02%)
PTC 47.24 Increased By ▲ 0.60 (1.29%)
SSGC 24.05 Increased By ▲ 0.23 (0.97%)
TBL 9.31 Increased By ▲ 0.07 (0.76%)
TELE 7.55 No Change ▼ 0.00 (0%)
TPL 25.00 Increased By ▲ 0.46 (1.87%)
TPLP 13.05 Increased By ▲ 0.06 (0.46%)
TREET 26.10 Increased By ▲ 0.12 (0.46%)
TRG 53.60 Increased By ▲ 0.27 (0.51%)
World

Britain approves J&J COVID-19 vaccine for use

  • Britain also cut its order for the single-dose shot, also known as J&J unit Janssen's vaccine, amid issues with the company's supply chain and reports of rare blood clots.
  • J&J's vaccine is already approved in the United States and European Union, where reports of rare blood clots are being reviewed.
Published Updated
By

LONDON: Britain's medicine regulator has approved Johnson & Johnson's COVID-19 vaccine for use, the health ministry said in a statement on Friday, making it the fourth COVID-19 shot available for use in the country.

Britain also cut its order for the single-dose shot, also known as J&J unit Janssen's vaccine, amid issues with the company's supply chain and reports of rare blood clots.

Britain has given two-thirds of the population a first dose of COVID-19, and the government cited the "unprecedented scale and pace" of the roll-out as behind the decision to cut its order to 20 million doses from the original order for 30 million doses.

"As Janssen is a single-dose vaccine, it will play an important role in the months to come as we redouble our efforts to encourage everyone to get their jabs and potentially begin a booster programme later this year," health minister Matt Hancock said.

J&J's vaccine is already approved in the United States and European Union, where reports of rare blood clots are being reviewed.

The shot uses similar viral vector technology to the Oxford-AstraZeneca vaccine, where similar clots have been reported.

Britain has advised that under-40s are offered an alternative to the AstraZeneca shot, and the government said that vaccine advisers the Joint Committee on Vaccination and Immunisation (JCVI) would also advise on how J&J's shot was used.

The government said the shot would be available later in the year. There have been reports that J&J expects to miss its delivery targets for the European Union this quarter.

Comments

Comments are closed for this article.